Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer

Hussein, Naglaa; Mohamed, Salwa Nayer; Ahmed, Mohamed A.

doi:10.1007/s12010-018-2858-4

Cited by 37 publications

(47 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In CRC samples, the cfDNA integrity index determined using the biocomposite platform was lower (0.18) than that obtained using the conventional method (0.27). This result confirmed that the biocomposite platform easily captured the small DNA fragments, which can be regarded as reliable evidence of the whole tumor burden 38 . The cellular DNA background using the biocomposite platform, the DNAs were amplified with the β-actin 400 bp primer.…”

Section: Synthesis and Optimisation Of Biocomposites A Protocol For supporting

confidence: 75%

A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers

Koo

Jun

Liu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Cell-free nucleic acids (cfNAs) in liquid biopsy samples are emerging as important biomarkers for cancer diagnosis and monitoring, and for predicting treatment outcomes. Many cfNA isolation methods have been developed recently. However, most of these techniques are time-consuming, complex, require large equipment, and yield low-purity cfNAs because the genetic background of normal cells is amplified during cell lysis, which limits their clinical application. Here, we report a rapid and simple cfNA sampling platform that can overcome the limitations of conventional methods. We synthesised a biocomposite by combining amine-modified diatomaceous earth (DE) and cucurbituril (CB). The biocomposite platform showed high capture efficiency (86.78–90.26%) with genomic DNA and amplified DNA products (777, 525 and 150 bp). The biocomposite platform allowed the isolation of high purity and quantity cfDNAs from the plasma of 13 cancer patients (three colorectal cancer and ten pancreatic cancer samples) without requiring a lysis step or special equipment. The biocomposite platform may be useful to isolate cfNAs for the diagnosis and treatment of cancers in clinical applications.

show abstract

Section: Synthesis and Optimisation Of Biocomposites A Protocol For supporting

confidence: 75%

A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers

Koo

Jun

Liu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In most clinical studies, cfDNA was suggested to be a promising diagnostic indicator . In addition, several reports on different cancers ascribed a prognostic value of cfDNA measurements to disease‐free or overall survival .…”

Section: Discussionmentioning

confidence: 99%

“…16 In most clinical studies, cfDNA was suggested to be a promising diagnostic indicator. 6,17,18 In addition, several reports on different cancers ascribed a prognostic value of cfDNA measurements to disease-free or overall survival. 19,20 However, data on the prediction and monitoring of therapy response in cancer patients undergoing NCT are limited.…”

Section: Discussionmentioning

confidence: 99%

Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer

Wang

Huang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

This study aimed to retrospectively evaluate the circulating free DNA (cfDNA) level in patients with locally advanced breast cancer (LABC) having different neoadjuvant chemotherapy (NCT) responses and to investigate whether dynamic changes in cfDNA level could predict the effectiveness of NCT in patients with LABC. Data on 61 patients with LABC were included. NCT responses were evaluated using the response evaluation criteria. Blood samples were collected for cfDNA detection before treatment and after the first and eighth courses of chemotherapy. The Alu 111‐bp and 260‐bp fragment levels were evaluated by polymerase chain reaction, and the predictive value of the cfDNA level in the NCT response was determined. In vitro, the MCF‐7 and MCF‐7/ADR cell lines were applied to simulate the phenomenon of drug resistance and explain the underlying mechanism. The Alu 111‐bp level increased after the first NCT course (P = .014) and then remained high after NCT in the high‐R group (P = .047), but it remained steady in the low‐R group during NCT. A similar tendency in the Alu 260‐bp level was revealed in different groups. The ∆∆Ct value of Alu 260‐bp had good diagnostic efficiency in assessing predictive ability. The area under the curve for the ∆∆Ct1 and ∆∆Ct2 of Alu 260‐bp was 0.697 and 0.647, respectively. The cfDNA level was closely related to epirubicin‐induced apoptosis and changes in the Ki‐67 index in vitro. The elevation of cfDNA after one chemotherapy cycle was mediated by the apoptosis of tumor cells and related to the improved chemotherapy response.

show abstract

“…Plasma ALU-247, ALU-115, and DNA integrity may be proven to have clinical utility in BC diagnosis. 64 In metastatic settings, Cheng et al showed a significantly increased cfDI (P = 1.21E-7 for ALU and P = 1.87E-3 for LINE1) in both Figure 1 The whole process of ctDNA analysis and possible influencing factors. Notes: The concentration of ctDNA and mutation frequency are significantly higher in ABC than early BC.…”

Section: The Cutoff Of Ctdna Concentrationmentioning

confidence: 97%

<p>Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer</p>

Liao¹,

Li²

2020

CMAR

View full text Add to dashboard Cite

Breast cancer (BC) represents the most commonly diagnosed cancer among females worldwide. Although targeted therapy has greatly improved the efficacy of treating BC, a large proportion of BC patients eventually develop recurrence or metastasis. Traditional invasive tumor tissue biopsy is short of comprehensiveness in tumor assessment due to heterogeneity. Liquid biopsy, an attractive non-invasive approach mainly including circulating tumor cell and circulating tumor DNA (ctDNA), has been widely utilized in a variety of cancers with the advances of sequencing technologies in recent years. The ctDNA that is found circulating in body fluids refers to DNA released from tumor cells and has shown clinical utility in metastatic breast cancer (MBC). With the results of genomic variants detection, ctDNA could be used to predict clinical outcomes, monitor disease progression, and guide treatment for patients with MBC. Moreover, the drug resistance problem may be addressed by ctDNA detection. In this review, we summarized the technological developments and clinical applications of ctDNA in MBC.

show abstract

Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer

Cited by 37 publications

References 24 publications

A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers

A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers

Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer

<p>Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer</p>

Contact Info

Product

Resources

About